

Title Page

Comparative hepatic and intestinal metabolism and pharmacodynamics of statins[#]

Anne M. Filppula, Päivi Hirvensalo, Heli Parviainen, Vilma E. Ivaska, K. Ivar Lönnberg, Feng Deng, Jenni Viinamäki, Mika Kurkela, Mikko Neuvonen, Mikko Niemi

Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland (A.M.F., P.H., H.P., V.E.I., K.I.L., F.D., J.V., M.K., M.Ne., M.Ni.)

Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland (A.M.F., P.H., H.P., V.E.I., K.I.L., F.D., J.V., M.K., M.Ne., M.Ni.)

Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland (M.Ni.)

Running Title Page

- a) **Running title:** *In vitro* metabolism and pharmacodynamics of statins
- b) **Corresponding author:** Prof. Mikko Niemi, P.O. Box 20, 00014 University of Helsinki, Finland, Phone: +358 50 428 0998, Fax: +358 9471 74039, E-mail: mikko.niemi@helsinki.fi
- c) **Number of**
- | | |
|--------------------------|-------------|
| - Text pages: | 17 |
| - Tables: | 2 |
| - Figures: | 4 |
| - References: | 50 |
| - Words in Abstract: | 194/250 |
| - Words in Introduction: | 706/750 |
| - Words in Discussion: | 1,497/1,500 |
- d) **Nonstandard abbreviations:** CL_{int} , intrinsic clearance; $C_{max,u}$, unbound peak concentration; CYP, cytochrome P450; HIM, human intestine microsome; HLC, human liver cytosol; HLM, human liver microsome; HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A; LC-MS/MS, liquid chromatography-tandem mass spectrometry; NADPH, nicotinamide adenine dinucleotide phosphate; PAPS, 3'-phosphoadenosine 5'-phosphosulfate; PMSF, phenylmethylsulfonyl fluoride; UDPGA, uridine 5'-diphospho-glucuronic acid; SULT, sulfotransferase; UGT, uridine diphosphate-glucuronosyltransferase.

Abstract

This study aimed to comprehensively investigate the *in vitro* metabolism of statins. The metabolism of clinically relevant concentrations of atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin and their metabolites were investigated using human liver microsomes (HLMs), intestine microsomes (HIMs), liver cytosol, and recombinant cytochrome P450 (CYP) enzymes. We also determined the inhibitory effects of statin acids on their pharmacological target, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. In HLMs, statin lactones were metabolized to a much higher extent than their acid forms. Atorvastatin lactone and simvastatin (lactone) showed extensive metabolism (intrinsic clearance (CL_{int}) values of 3,700 and 7,400 $\mu\text{l}/\text{min}/\text{mg}$), while the metabolism of the lactones of 2-hydroxyatorvastatin, 4-hydroxyatorvastatin, and pitavastatin was slower (CL_{int} 20-840 $\mu\text{l}/\text{min}/\text{mg}$). The acids had CL_{int} values in the range <0.1 -80 $\mu\text{l}/\text{min}/\text{mg}$. In HIMs, only atorvastatin lactone and simvastatin (lactone) exhibited notable metabolism, with CL_{int} values corresponding to 20% of those observed in HLMs. CYP3A4/5 and CYP2C9 were the main statin-metabolizing enzymes. The majority of the acids inhibited HMG-CoA reductase with 50% inhibitory concentrations of 4-20 nM. The present comparison of the metabolism and pharmacodynamics of the various statins using identical methods provides a strong basis for further application, e.g., comparative systems pharmacology modelling.

Significance Statement

The present comparison of the *in vitro* metabolic and pharmacodynamic properties of atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin and their metabolites using unified methodology provides a strong basis for further application. Together with *in vitro* drug transporter and clinical data, our findings are applicable for use in comparative systems pharmacology modelling to predict the pharmacokinetics and pharmacological effects of statins at different dosages.

Introduction

3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely used in the treatment of hypercholesterolemia. Although statin drugs are effective and safe in most patients, many users experience poor efficacy or adverse drug reactions (Pazzucconi *et al.*, 1995; Yebyo *et al.*, 2019). The muscle toxicity of statins is a dose- and concentration-dependent phenomenon (Bradford *et al.*, 1991; Dujovne *et al.*, 1991), and the risk of toxicity increases along with the plasma concentrations of statins. This may be caused by drug-drug interactions or inherited defects in proteins affecting statin disposition, such as cytochromes P450 (CYP) 2C9 and 3A4, organic anion transporting polypeptide (OATP) 1B1 or breast cancer resistance protein (BCRP) (Thompson *et al.*, 2003; Graham *et al.*, 2004; Neuvonen *et al.*, 2006; Pasanen *et al.*, 2006; Keskitalo *et al.*, 2009b; Hirvensalo *et al.*, 2019).

Both acid and lactone forms of statins can interact with proteins involved in drug disposition. Lovastatin and simvastatin are administered as lactone prodrugs, whereas other statins are given in the active acid form. In the body, however, significant amounts of many statins are converted to their corresponding acid/lactone form (Neuvonen *et al.*, 2006). CYP enzymes metabolize the lipophilic statin lactones more rapidly than statin acids (Fujino *et al.*, 2004). Indirectly, uridine diphosphate-glucuronosyltransferase (UGT) enzymes may participate in lactone formation by mediating glucuronidation of statin acids. The acyl glucuronides formed in this process may then undergo spontaneous cyclization to the statin lactone (Prueksaritanont *et al.*, 2002). CYP3A4 plays a key role in the elimination of atorvastatin, lovastatin, and simvastatin (Neuvonen *et al.*, 2006). In turn, the 3R,5S- and 3S,5R-enantiomers of fluvastatin are extensively biotransformed by CYP2C9 (Fischer *et al.*, 1999; Hirvensalo *et al.*, 2019). Pitavastatin, pravastatin, and rosuvastatin are excreted mainly unchanged (Neuvonen *et al.*, 2006). Hence, the available statins differ significantly in their pharmacokinetic characteristics and susceptibility to altered metabolizing enzyme function.

Interestingly, the pharmacological target of statins, HMG-CoA reductase, is expressed in the same location as the CYP enzymes, the endoplasmic reticulum of hepatocytes (Corsini *et al.*, 1995). Thus, this enzyme is also present

in human liver microsomes (HLMs). Similar to CYPs, the active site of HMG-CoA reductase faces the cytoplasm and the enzyme uses nicotinamide adenine dinucleotide phosphate (NADPH) for its catalytic activity (Corsini *et al.*, 1995). Statin acids, which are structurally similar to its substrate HMG-CoA, competitively inhibit it in the nanomolar range, leading to a reduction of the HMG-CoA-mevalonate pathway. Also several statin metabolites have been depicted to be inhibitors of this reaction, but *in vitro* data for e.g. the 2- and 4-hydroxy metabolites of atorvastatin do not seem to be publically available.

Many published physiologically-based pharmacokinetic (PBPK) models of statins can be found in the literature, primarily aiming to evaluate their drug-drug interaction and pharmacogenetic properties. During the past two decades, PBPK modelling has evolved as an important tool in drug development, regulatory review, and clinical study design (Sager *et al.*, 2015). PBPK modelling also holds the potential to become a valuable tool to inform drug and dosing selection in clinical practice (Johnson and Rostami-Hodjegan, 2011; Jamei, 2016; Venkatakrishnan and Rostami-Hodjegan, 2019). For such purposes, it is crucial that the data used for model development of a set of drugs are comparable and high in quality. Although the metabolism of statins has been widely investigated *in vitro*, only a few substrate depletion studies comparing the microsomal metabolism of different statins have been published (Fujino *et al.*, 2004; Gertz *et al.*, 2010; Gertz *et al.*, 2011; Varma *et al.*, 2014). When appropriately applied, the substrate depletion approach results in intrinsic clearance (CL_{int}) values, which include all microsomal metabolic pathways of the tested compound (Obach, 1999) and can be scaled to hepatic metabolic clearance for PBPK modelling. Hence, to obtain comparable estimates of the metabolism of the widely used statins atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin and their metabolites, we carried out an extensive *in vitro* study in subcellular hepatic and intestinal fractions as well as in recombinant CYP enzymes using low, clinically relevant statin concentrations. Moreover, to simulate the pharmacological response of statins in PBPK models, unbound statin concentrations in hepatocytes can be linked to *in vitro* measurements of their pharmacodynamic potency. Therefore, we also compared the inhibitory effects of these statins on their pharmacological target HMG-CoA reductase.

Materials and Methods

Chemicals and reagents

Atorvastatin (acid), atorvastatin lactone, 2-hydroxyatorvastatin (acid), 2-hydroxyatorvastatin lactone, 4-hydroxyatorvastatin (acid), 4-hydroxyatorvastatin lactone, mevalonate lactone, pravastatin (acid), rosuvastatin (acid) and all internal standards (**Supp. Table 1**) were purchased from Toronto Research Chemicals (Toronto, Canada). 3R,5S-fluvastatin (acid), 3S,5R-fluvastatin (acid), pitavastatin (acid), and pitavastatin lactone were obtained from Santa Cruz Biotechnology (Dallas, Texas), and simvastatin acid and simvastatin (lactone) from SynFine Research (Ontario, Canada). Adenosine 3-phosphate 5'-phosphosulfate triethylammonium salt (PAPS), alamethicin, NADPH, uridine 5'-diphospho-glucuronic acid (UDPGA), and HMG-CoA reductase assay kits were obtained from Sigma-Aldrich (St. Louis, MO). HLMs (XTreme 200, a pool of 200 mixed gender donors), human liver cytosol (HLC; XTreme 200, a pool of 200 mixed gender donors), and human intestine microsomes (HIMs) both normal (a pool of 15 mixed gender donors) and free from phenylmethylsulfonyl fluoride (PMSF; optimal in carboxylesterase activity; a pool of 6 mixed gender donors) were purchased from Sekisui XenoTech (Tokai, Japan). The following recombinant EasyCYP Bactosomes were obtained from Cypex Ltd (Dundee, UK): CYP1A2R, CYP2A6BR, CYP2B6BR, CYP2C8BR, CYP2C9BHR, CYP2C19BR, CYP2D6R, CYP2E1BR, CYP2J2LR, CYP3A4BR, and CYP3A5BLR. Other chemicals were from Merck (Darmstadt, Germany).

Metabolism in human liver microsomal incubations

The metabolic depletion of statins was first measured in HLMs. With the exception for buffer controls, all incubations contained substrate, microsomes (0.2 mg/ml) in sodium phosphate buffer (0.1 M, pH 7.4) with MgCl₂ (5 mM). For simvastatin, the protein concentration was reduced to 0.1 mg/ml after the initial experiment. The depletion of each parent statin and its corresponding acid/lactone was studied in four different conditions: 1) addition of NADPH (1 mM) to the reaction mixture to measure the CYP-mediated metabolism, 2) addition of NADPH (1 mM), UDPGA (5 mM) to measure both CYP- and UGT-mediated metabolism, 3) no addition of cofactors (negative control), and 4) no addition of cofactors nor microsomes (buffer control). In condition 2)

alamethicin (11 µg/ml) was also included in the incubations to allow pore formation. The metabolism of the 2- and 4-hydroxy metabolites of atorvastatin were studied using conditions 1), 3) and 4). The initial incubation concentrations of each substrate are listed in **Table 1 and Supp. Table 2**.

All incubations were carried out once in triplicate on 96-well plates. The mixtures of substrate and microsomes (or only substrate in buffer in 4)) were first preincubated for 15 min at 37°C and 350 rpm. Following preincubation, cofactors were added to initiate the reactions in 1) and 2). Samples were taken at 0, 5, 10, 20, 40, and 60 min. For atorvastatin lactone and simvastatin, the sampling times were shorter (0.5, 1, 3, 5, 7, and 10 min). Reactions were stopped by diluting samples 1:3 with of ice-cold acetonitrile containing internal standard (1:2 for rosuvastatin) (**Supp. Table 1**), and further handled as described below in the section Sample processing and analysis of metabolism samples.

Metabolism in human intestine microsomal incubations

The metabolic depletion of parent statins and their corresponding acid/lactone was also measured in HIMs. With the exception of buffer controls, all incubations contained substrate, microsomes (0.2 mg/ml) in sodium phosphate buffer (0.1 M, pH 7.4) with MgCl₂ (5 mM). For each substrate (incubation concentrations listed in **Table 1 and Supp. Table 2**), the depletion was studied in four different conditions: 1) addition of NADPH (1 mM) and UDPGA (5 mM) to measure both CYP- and UGT-mediated metabolism (alamethicin 11 µg/ml also included), 2) no addition of cofactors (negative control), and 3) no addition of cofactors nor microsomes (buffer control). Furthermore, to screen for the potential effects of intestinal carboxylesterases on the metabolism of statins, each statin was also incubated with 4) 0.2 mg/ml PMSF-free HIMs (optimal in esterase activity). No cofactors were added to PMSF-free HIM incubations.

All incubations were carried out once in triplicate, preincubated and stopped in a similar manner as described for the HLM incubations above. In 1-3), samples were taken at 0, 5, 10, 20, and 45 min. In 4) only two samples were taken: at 0 and 25 min.

Metabolism screening in human cytosolic incubations

To screen for statin metabolism mediated by cytosolic enzymes, each statin was incubated with HLC (0.2 mg/ml) in sodium phosphate buffer (0.1 M, pH 7.4) with MgCl₂ (5 mM) at 37°C and 350 rpm, either 1) without co-factors or 2) with the sulfotransferase (SULT) cofactor PAPS (100 μM). Two samples were taken: 0 and 25 min. These conditions were selected to match those of the HIM screening (test setting 4) above). All incubations were carried out once in triplicate and reactions were stopped as above.

Metabolism screening with recombinant CYP enzymes

The depletion of statins was also measured in recombinant CYP incubations. In the screening, the substrates were incubated with each one of 11 CYP isoforms (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP2J2, CYP3A4, and CYP3A5) separately at a protein concentration of 0.2 mg/ml. The substrate concentrations were the same ones as in the HLM depletion experiment (**Table 1, Supp. Table 2**). Samples were collected at 0, 30, and 60 min. All incubations were carried out once in triplicate and reactions were stopped as above.

Inhibition of metabolism in microsomal incubations

To confirm the results from the recombinant CYP screening, inhibition studies in HLMs and HIMs were carried out for selected statins (HLMs: atorvastatin and atorvastatin lactone, 3R,5S- and 3S,5R-fluvastatin, pitavastatin lactone, simvastatin and simvastatin acid; HIMs: atorvastatin lactone and simvastatin). In HLMs, inhibition of CYP3A4 and CYP isoforms causing ≥50% depletion at 60 min in the CYP screening were tested. The substrate and NADPH concentrations used were identical to those used in the microsomal depletion experiments above (**Table 1, Supp. Table 2**). The protein concentration was 0.2 mg/ml in atorvastatin and atorvastatin lactone experiments, 0.5 mg/ml in 3R,5S-fluvastatin and 3S,5R-fluvastatin, pitavastatin lactone, and simvastatin acid experiments, and 0.1 mg/ml in simvastatin experiments. Ketoconazole (1 μM), montelukast (5 μM), quinidine (10 μM), and sulfaphenazole (10 μM) were employed as competitive inhibitors of CYP3A4/5, CYP2C8, CYP2D6, and CYP2C9, respectively. Because of concerns regarding the selectivity of montelukast and quinidine, the effects

of the time-dependent inhibitors gemfibrozil glucuronide (60 μM ; CYP2C8) and paroxetine (15 μM ; CYP2D6) were also tested. Whereas inhibitor and substrate were co-incubated in direct inhibition experiments, the experiment with paroxetine included a 15 min preincubation of inhibitor and NADPH and HLMs before addition of substrate. The experiment with gemfibrozil glucuronide was initiated by preincubating inhibitor with NADPH in HLMs. After preincubation for 15 min, 10 μl of the preincubation mix was moved to another well containing 190 μl statin and NADPH in buffer, diluting the protein concentration 20-fold. Samples in the inhibition experiments were taken at the same time points as in the HLM depletion experiment described above or at 0.5, 2, 4, 6, 8, and 10 min (atorvastatin lactone). In HIM incubations, the protein concentration was 0.2 mg/ml and only the effects of ketoconazole (1 μM) were tested. For atorvastatin lactone, samples were taken at 0, 5, 10, 20 and 45 min, and for simvastatin at 0, 3.5, 5, 7.5, and 10 min. All HLM and HIM incubations were carried out once in triplicate at 37°C and 350 rpm, and stopped as described above.

Determination of unbound fraction in microsomes

Unbound fraction in microsomes ($f_{u,mic}$) values were measured using two-chambered Rapid Equilibrium Dialysis (RED) devices (Thermo Scientific, Waltham, MA, USA). HLMs (0.2 mg/ml; 0.1 mg/ml for simvastatin) or HIMs (0.2 mg/ml) in buffer (200 μl) containing statin were transferred to one chamber and 400 μl buffer to the other, before incubation at 37°C for 4 h on a shaker (300 rpm). At the end of the incubation, 25 μl samples from the HLM and buffer chambers were transferred to a 96-well plate containing 100 μl internal standard in acetonitrile. Blank buffer or blank HLMs or HIMs (25 μl) was added to the samples from the HLM or buffer chambers, respectively, to yield identical matrices. Samples were thereafter processed as described previously. The $f_{u,mic}$ was calculated by dividing the statin concentration in buffer by that in the microsomal incubation mixture. To minimize potential metabolism by enzymes not dependent on external cofactors for their activity, old microsomes with several freeze-and thaw cycles were used. In addition, they were allowed to incubate in room temperature 8 h prior to the experiment. Denaturation was not carried out because of concerns that it would lead to conformational changes of the microsomal structure.

Inhibition of HMG-CoA

To investigate the inhibitory effects of statins on their pharmacological target HMG-CoA reductase, we first determined the time-linearity of HMG-CoA metabolism at different enzyme concentrations (0.3-1.2 $\mu\text{g/ml}$). Herein, incubations containing HMG-CoA (30 μM) and HMG-CoA reductase in phosphate buffer (0.1 M) were first preincubated for 5 min at 37°C before addition of NADPH (4.5 mM), which initiated the reactions. Reactions were stopped by placing 50 μl samples in 150 μl ice-cold acetonitrile containing mevalonolactone-d₃ as the internal standard. Based on the obtained data, we determined the enzyme kinetics of HMG-CoA to its metabolite mevalonate by preincubating HMG-CoA (5-240 μM) with HMG-CoA reductase (0.9 $\mu\text{g/ml}$) in phosphate buffer for 3 min. NADPH was added and the reactions were allowed to continue for 3 min before stopping them as described above. The same preincubation and incubation times (3+3 min) were also used in the final inhibition experiments. Herein, eight different concentrations of the statin acids (0-500 nM) were simultaneously incubated with HMG-CoA at 20 μM and HMG-CoA reductase (0.9 $\mu\text{g/ml}$) and NADPH in buffer. All incubations were performed once in triplicate. Use of recombinant enzyme was preferred over HLMs to avoid CYP-mediated metabolism of statins.

Sample processing and analysis of metabolism samples

After sample collection, metabolism samples were kept on ice for at least 10 min before centrifugation at 2,000 *g* for 10 min. All samples were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). The drug concentrations in HLM and recombinant CYP enzyme incubations were determined using a Nexera X2 liquid chromatograph (Shimadzu, Kyoto, Japan) coupled to an API3000 tandem mass spectrometer (AB Sciex, Toronto, Ontario, Canada), as previously described for atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin (Keskitalo *et al.*, 2009a; Keskitalo *et al.*, 2009b; Keskitalo *et al.*, 2009c; Itkonen *et al.*, 2015; Lehtisalo *et al.*, 2020). Part of the samples (HIM, HLC, RED and some inhibition incubations) were analyzed using a Sciex 5500 Qtrap LC-MS/MS system (AB Sciex) interfaced with an ESI ion source. The chromatographic separation was carried out on a Luna Omega polar C18 column (100x2.1mm I.D., 1.6 μm particle size; Phenomenex, Torrance, CA) using 5 mM ammonium formate (pH 3.9, adjusted with 98% formic acid) as mobile phase A and

acetonitrile as mobile phase B. The flow rate and the column temperature were maintained at 300 $\mu\text{L}/\text{min}$ and 40 $^{\circ}\text{C}$. The following gradient conditions were applied: 1 min at 20% B on hold, then a linear ramp from 20% B to 40% B over 3 min followed by a second linear ramp to 90% B over 2 min, and 1 min at 90% B before a re-equilibration step back to the initial conditions (20% B). The characteristic multiple reaction monitoring (MRM) transitions for each analyte and internal standard are presented in **Supp. Table 1**.

Sample processing and analysis of pharmacodynamic samples

Following sample collection, samples were kept on ice, and 10 μl HCl (5 M) was added to ensure the lactonization of mevalonic acid into mevalonolactone (Honda *et al.*, 2007). Samples were centrifuged at 2,000 g for 10 min before LC-MS/MS analysis. Analytes were separated on Kinetex C18, 2.6 μm , 100 x 2.1 mm with SecurityGuard™ ULTRA C18 2 x 2.1 mm column (Phenomenex, Torrance, CA, USA) by liquid chromatography (Nexera X2, UHPLC system, Shimadzu, Kyoto, Japan) with 0.05% formic acid as mobile phase A and acetonitrile as mobile phase B at flow rate 0.2 ml/min. The mobile phase B was kept at 30% for 0-1.5 min, increased to 100% for 1.6-3.5 min and balanced at 30% before next injection. The analytes were detected in a Shimadzu LCMS-8050 mass spectrometer (Shimadzu, Kyoto, Japan) operated in positive electrospray ionization mode (ESI+) and the multiple reaction monitoring transitions $[\text{M}+\text{H}]^+$ were m/z 130.9-43.0 for mevalonolactone and m/z 133.9 – 45.95 for the internal standard.

Data analysis and *in vitro-in vivo* extrapolation

The obtained data of the present *in vitro* experiments were analyzed using GraphPad Prism software (version 7.03; GraphPad Software, Inc., San Diego, CA). For depletion data, pseudo-first-order depletion rate constants (k_{dep}) were determined using nonlinear regression analysis ($C=C_0 \times e^{-k_{\text{dep}} \times t}$, where C is the observed concentration, C_0 the initial concentration, and t the incubation time). Only data points in the log-linear portion of each depletion curve were included in the analyses. Statin depletions observed in incubations with cofactors were corrected for depletions in incubations lacking cofactors (negative controls) by $k_{\text{dep, corrected}} = k_{\text{dep, incubation}} - k_{\text{dep, negative control}}$. Assuming that substrate concentrations were $\ll K_m$ for their metabolic pathways, their intrinsic clearance in depletion experiments was expressed as $\text{CL}_{\text{int}} = k_{\text{dep, corrected}} / [\text{M}]$, where $[\text{M}]$ is the microsomal protein concentration

or CYP concentration in recombinant enzyme incubations (Obach, 1999). Percent inhibition of statin depletion was calculated by comparing CL_{int} values of incubations containing inhibitor to those lacking inhibitor. The mean of statin CL_{int} in the presence of each inhibitor was compared with the control using the Student's t test in IBM SPSS Statistics (version 27.0; IBM Corp., Armonk, NY, USA). A P value < 0.05 was considered statistically significant. Unbound intrinsic clearance values, $CL_{int,u}$, were calculated according to $CL_{int,u} = CL_{int} / f_{u,mic}$. For pharmacodynamic data, statin concentration values producing 50% inhibition (IC_{50}) were determined using nonlinear regression in GraphPad Prism, and related to their unbound peak concentrations in plasma ($C_{max,u}$) and in the portal vein.

Results

Metabolism in microsomal and cytosolic incubations

In HLM incubations, statin lactones were metabolized to a much higher extent than their corresponding acid forms (**Fig. 1A and 2A, Supp. Table 3**). In incubations with NADPH, atorvastatin lactone and simvastatin showed extensive metabolism (CL_{int} values of 3,700 and 7,400 $\mu\text{l}/\text{min}/\text{mg}$), while the metabolism of the lactones of 2-hydroxyatorvastatin, 4-hydroxyatorvastatin, and pitavastatin was slower (CL_{int} 20-840 $\mu\text{l}/\text{min}/\text{mg}$). The statin acids had CL_{int} values in the range of <0.1 -80 $\mu\text{l}/\text{min}/\text{mg}$. For most parent statins, the metabolism of both acid and lactone forms in NADPH+UDPGA incubations was of similar range or slightly slower than in NADPH incubations. No metabolism was observed in pitavastatin acid, pravastatin, and rosuvastatin incubations. In most HLM control incubations lacking cofactors (negative controls), the depletion of statins was $<20\%$ at 60 min (**Fig. 2A**). However, in control incubations containing simvastatin and 4-hydroxyatorvastatin lactone, there seemed to be some CYP- and UGT-independent depletion occurring; for simvastatin the depletion was 29% at 60 min and for 4-hydroxyatorvastatin lactone, it was 32%. Pitavastatin lactone exhibited large variation due to limited solubility, which was observed repeatedly across experiments. For most statins, the solubility seemed to be dependent on the presence of microsomal protein; the initial concentrations in buffer controls were often lower than in corresponding incubations containing microsomes and the solubility seemed to increase with incubation time in buffer controls (data not shown). In the HLC screening, no clear statin metabolism was evident, neither with nor without PAPS (**Fig. 2B**).

In HIM incubations with NADPH and UDPGA, only atorvastatin lactone and simvastatin showed notable metabolism (**Fig. 1B and 2C, Supp. Table 4**). The HIM CL_{int} values of atorvastatin lactone and simvastatin corresponded to approximately 20% of those obtained in HLM incubations. Following incubation for 20-25 min, no clear metabolism was observed in HIM incubations lacking cofactors, except for a slight 17% decrease in simvastatin acid concentration in PMSF-free HIM incubations (**Fig. 2C**). For atorvastatin, atorvastatin lactone, and pravastatin, the decrease was 10-12%. For pitavastatin lactone, the concentration seemed to have increased

with time. This is likely due to solubility issues, which were also observed in other incubations with pitavastatin lactone. $f_{u,mic}$ values varied markedly between the statins (**Supp. Tables 3 and 4**)

Metabolism screening with recombinant CYP enzymes

In the recombinant CYP screening, CYP3A4, CYP3A5, CYP2D6, CYP2C9, and CYP2C8 were the most active enzymes involved in statin metabolism (**Fig. 2A**). Following incubation for 60 min, $\leq 50\%$ of the initial substrate concentration remained in CYP3A4 incubations with atorvastatin lactone, 2-hydroxyatorvastatin lactone, 4-hydroxyatorvastatin lactone, pitavastatin lactone, simvastatin, and simvastatin acid. The same ($< 50\%$ remaining of the initial statin concentration) was observed in CYP3A5 incubations for atorvastatin lactone, 2-hydroxyatorvastatin lactone, and simvastatin, in CYP2D6 incubations for atorvastatin lactone, 2-hydroxyatorvastatin lactone, and pitavastatin lactone, in CYP2C9 incubations for the fluvastatin enantiomers, in CYP2C8 incubations for 2-hydroxyatorvastatin lactone and simvastatin, and in CYP1A2 and CYP2A6 incubations for 2-hydroxyatorvastatin lactone. Of note, whereas the lactones of atorvastatin, 2-hydroxyatorvastatin and simvastatin were completely metabolized by both CYP3A4 and CYP3A5, their acid forms were more prone to metabolism by CYP3A4 than by CYP3A5.

Inhibition of metabolism in microsomal incubations

In HLMs, the CYP3A4 inhibitor ketoconazole completely ($> 95\%$) inhibited the metabolism (CL_{int}) of atorvastatin ($P < 0.001$) and atorvastatin lactone ($P = 0.004$), and that of simvastatin ($P = 0.002$) and simvastatin acid ($P < 0.001$) (**Fig. 3**). It had no effect ($< 10\%$ inhibition) on the depletion of 3S,5R-fluvastatin ($P = 0.142$), whereas it had a moderate effect on the CL_{int} of 3R,5S-fluvastatin (35% inhibition, $P = 0.027$) and that of pitavastatin lactone (18%, $P = 0.343$). In turn, the CYP2C9 inhibitor sulfaphenazole inhibited the CL_{int} of 3R,5S-fluvastatin and 3S,5R-fluvastatin by 42% ($P < 0.001$) and 51% ($P = 0.010$). The CYP2D6 inhibitor quinidine inhibited the depletion of atorvastatin lactone by 18% ($P = 0.093$) and pitavastatin lactone by 18% ($P = 0.241$). Paroxetine inhibited the depletion of atorvastatin lactone by 16% ($P = 0.106$). The CYP2C8 inhibitor montelukast inhibited the depletion of simvastatin by 25% ($P = 0.101$), whereas gemfibrozil glucuronide had no effect on it ($P = 0.840$). In HIMs, ketoconazole inhibited the metabolism of atorvastatin lactone and simvastatin by $> 95\%$ ($P < 0.001$ and $P < 0.001$).

Interconversion between acid and lactone forms in microsomal and cytosolic incubations

Some interconversion between statin acid and lactone forms could be detected for atorvastatin, pitavastatin, and simvastatin. To examine the extent of interconversion in HIMs, we quantified the concentrations of the corresponding lactone in statin acid incubations and those of the corresponding acid in lactone incubations (**Supp. Fig. 1**). For other incubations, the data described reflect qualitative data.

In HIMs supplemented with NADPH + UDPGA, lactone concentrations marginally increased in pitavastatin but not in atorvastatin incubations (**Supp. Fig. 1**). In HLMs with NADPH and UDPGA, the lactone concentrations of both atorvastatin and pitavastatin slightly increased, but not in other incubations (NADPH, control). For simvastatin acid, there was no increase in lactone in HLMs and HIMs. In other incubations (PMSF-free HIMs, HLC ± PAPS) with these statin acids, no increase in lactone was observed.

For statin lactones, there seemed to be a trend towards increase of acid concentrations in negative control (no cofactor) HLM and HIM incubations, in PMSF-free HIMs (no cofactor added) and in HLC (±PAPS). More specifically, for atorvastatin lactone, acid concentrations increased up to 8% and 13% of the initial lactone concentration in NADPH+UDPGA and no cofactor HIM incubations, respectively (**Supp. Fig. 1**). In NADPH incubations, no increase in acid concentrations was observed. In HLMs, acid concentrations increased in negative control incubations, but not in those containing cofactors. In PMSF-free HIMs and HLC, the atorvastatin acid concentrations seemed to increase slightly.

For pitavastatin lactone, acid concentrations slightly increased in all incubations. For simvastatin, there seemed to be an increase in acid concentrations (up to 10% of the initial simvastatin concentration) in HIMs lacking cofactors but not in those containing cofactors (**Supp. Fig. 1**). In HLMs, there was no increase in acid concentrations. In PMSF-free HIMs and HLC, the acid concentrations seemed to increase slightly.

Inhibition of HMG-CoA

In enzyme kinetic experiments, the kinetics of HMG-CoA was best described by a substrate inhibition model, with K_m , K_i , and V_{max} values corresponding to 13 μM , 105 μM , and 1,582 nmol/min/mg (**Supp. Fig. 2**). In pharmacodynamic experiments, the majority of the statin acids tested inhibited the HMG-CoA-mevalonate reaction with IC_{50} values in the range 4-20 nM (**Table 2, Fig. 4**). The IC_{50} of 3R,5S-fluvastatin was 9 nM, whereas that of its 3S,5R enantiomer approximated to 100 nM. Similarly, the IC_{50} of 2-hydroxyatorvastatin acid was 12 nM, but that of 4-hydroxyatorvastatin acid corresponded to ~ 100 nM. While the IC_{50} values of most statins were relatively close to their typical unbound peak concentrations in plasma (**Fig. 4**), those of 3S,5R-fluvastatin and simvastatin acid exceeded clinically relevant concentrations of 3S,5R-fluvastatin and simvastatin acid by 26-35-fold.

Discussion

This study aimed to comprehensively investigate and compare the metabolism and pharmacodynamics of fourteen statins or statin metabolites using identical methods. Our collective data from HLM, HIM, HLC, and recombinant enzyme incubations, underlines the importance of CYP enzymes in statin metabolism. According to our findings, CYP3A4/5 (simvastatin, atorvastatin) and CYP2C9 (fluvastatin) are the main statin-metabolizing enzymes in the liver. In HLMs, statin lactones were metabolized to a much higher extent than their corresponding acids. No or very little statin depletion occurred in the liver cytosol. In HIMs, CYP3A4/5 extensively metabolized atorvastatin lactone and simvastatin. No intestinal or hepatic metabolism was observed for pitavastatin, pravastatin and rosuvastatin. In the pharmacodynamic experiment, the majority of the statin acids inhibited HMG-CoA reductase with IC_{50} values of 4-20 nM. Collectively, our findings are applicable for use in comparative systems pharmacology modelling of statins.

Although statin metabolism has been widely investigated *in vitro*, only a few depletion studies comparing the metabolism of statins have been published (Fujino *et al.*, 2004; Gertz *et al.*, 2010; Gertz *et al.*, 2011; Varma *et al.*, 2014), and none with the present palette of statins. Our HLM and HIM CL_{int} values were generally within two-fold of the previous CL_{int} values from depletion studies. In agreement with previous knowledge (Fujino *et al.*, 2004), the lactones were metabolized more extensively than their acid forms. Atorvastatin lactone and simvastatin showed extensive metabolism with HLM CL_{int} values of 3,700 and 7,400 $\mu\text{l}/\text{min}/\text{mg}$, while those of the lactones of 2-hydroxyatorvastatin, 4-hydroxyatorvastatin, and pitavastatin were in the range 20-840 $\mu\text{l}/\text{min}/\text{mg}$. The statin acids had CL_{int} values below 80 $\mu\text{l}/\text{min}/\text{mg}$, with pitavastatin acid, pravastatin, and rosuvastatin showing negligible metabolism. In HIMs, only atorvastatin lactone and simvastatin exhibited notable metabolism, with CL_{int} values corresponding to 20% of those obtained in HLMs. As compared to incubations with NADPH as the single cofactor, UDPGA addition did not result in an increased depletion. This indicates that the role of UGTs in the overall statin metabolism is relatively small.

To verify the CYPs involved in statin metabolism and to evaluate the potential role of the poorly characterized CYP2J2, we carried out an extensive screening in a panel of eleven recombinant CYPs. Here, CYP3A4, CYP3A5, CYP2D6, CYP2C9, and CYP2C8 were the most active enzymes. CYP2J2 exhibited some activity towards atorvastatin lactone, 2-hydroxyatorvastatin lactone, pitavastatin lactone, simvastatin, and simvastatin acid. On the other hand, these compounds were metabolized to various degrees by almost all CYPs tested. Our inhibition data in HLMs and HIMs demonstrated a major role for CYP3A4/5 in the metabolism of atorvastatin, atorvastatin lactone, simvastatin acid, and simvastatin, in line with clinical observations (Neuvonen *et al.*, 2006). For fluvastatin, CYP2C9 was of greater importance than CYP3A4. Furthermore, CYP2C9 was more prominent in the metabolism of 3S,5R-fluvastatin than in that of its enantiomer, as described earlier (Hirvensalo *et al.*, 2019). Pitavastatin lactone was markedly metabolized by CYP2D6 and CYP3A4 in the screening, but its depletion was inhibited only moderately by the corresponding inhibitors in HLMs. Overall, our data demonstrating key roles for CYP3A4 and CYP2C9 in statin metabolism are in line with previous literature (Fujino *et al.*, 2004; Neuvonen *et al.*, 2006).

The interconversion between the acid and lactone forms of statins introduces an additional level of complexity into statin pharmacokinetics. The process can be enzyme-mediated, spontaneous or pH-driven, and occur in both the blood stream and hepatocytes (Jemal *et al.*, 1999; Billecke *et al.*, 2000; Prueksaritanont *et al.*, 2002; Hoffmann and Nowosielski, 2008; Li *et al.*, 2019). In line with previous studies (Prueksaritanont *et al.*, 2002; Fujino *et al.*, 2003; Yamada *et al.*, 2003), we observed slight increase in lactone concentrations in some statin acid incubations with UDPGA. The underlying mechanism is likely UGT-mediated glucuronidation, followed by spontaneous lactonization (Prueksaritanont *et al.*, 2002). For statin lactones, there was a trend towards increase of acid concentrations in negative control microsomal incubations, suggesting a role for enzymes that do not require external cofactors for their activity, such as carboxylesterases (Liederer and Borchardt, 2006). In PMSF-free HIMs, however, less than 10% of the initial lactone concentrations had been depleted at 25 min. For comparison, in HIMs fortified with NADPH and UDPGA, only 32% and <1% of the initial atorvastatin lactone and simvastatin (lactone) remained at 20 min. Thus, the role of intestinal membrane-bound esterases in lactone depletion seems to

be negligible. There are contradictory findings on the role of human carboxylesterases in the conversion of simvastatin to its acid form; however, these enzymes seem to catalyze this process in blood (Vickers *et al.*, 1990; Wang *et al.*, 2015; Li *et al.*, 2019). Together with SULTs, carboxylesterases are also present in smaller fractions in the cytosol (Boberg *et al.*, 2017). In our HLC incubations (\pm PAPS), no statin showed a $>10\%$ reduction in their concentrations at 25 min. No depletion was observed for pravastatin, which has been reported to be a SULT substrate in rat liver (Kitazawa *et al.*, 1993; Watanabe *et al.*, 2009). As a longer incubation time might have shown some involvement of cytosolic enzymes in statin metabolism, our HLC data should be interpreted with caution.

We used substrate depletion to obtain comparable estimates of the microsomal metabolism of each statin. The depletion approach operates under the assumption that the initial substrate concentration is well below K_m ($C_0 \ll K_m$) (Obach, 1999). In our experiments, we attempted to use equal protein concentrations (0.2 mg/ml; 0.1 mg/ml for simvastatin) and low, clinically relevant statin concentrations. For most statins, an incubation concentration of 0.05 μ M was used. For pitavastatin acid and lactone, and rosuvastatin the corresponding concentrations were slightly lower (0.01-0.04 μ M), and for pravastatin it was higher (0.1 μ M), based on initial estimations of typical unbound plasma concentrations. Regardless, in HLM incubations, the $C_0 \ll K_m$ criterion was fulfilled for all statins with K_m values reported in the literature (**Supp. Table 2**). Assuming a ‘worst case’ scenario with complete absorption of the statin into enterocytes, our initial substrate concentrations in HIMs were in general 20-fold higher than those in HLMs. For the fluvastatin enantiomers, the concentrations used did not fulfill the $C_0 \ll K_m$ criterion in HIMs. However, no fluvastatin metabolism was observed in HIM incubations, and also the metabolism in HLMs was limited.

The present microsomal experiments included both buffer controls and negative controls. As most statins needed protein to dissolve in the incubations, it was not possible to distinguish between potential degradation of compound in buffer and depletion in incubations lacking cofactors. However, by correcting for depletion in negative control incubations, we were able to accurately measure the NADPH- and UDPGA-dependent microsomal metabolism. Use of microsomes instead of hepatocytes allowed us to measure metabolic CL_{int} values in a system stripped from confounding factors, such as drug transporters. Interestingly, while rosuvastatin is not metabolized in microsomes,

there are data showing (very slow) rosuvastatin metabolism in hepatocytes (McCormick *et al.*, 2000). The statins are known substrates of drug transporters, in particular of OATP1B1 and BCRP (Pasanen *et al.*, 2006; Keskitalo *et al.*, 2009c; Giacomini *et al.*, 2013). Consequently, the hepatic clearance of statins is a product of their metabolic CL_{int} values in combination with their transporter CL_{int} values. Together with *in vitro* drug transport and pharmacodynamic data in combination with clinical data, our CL_{int} values can be applied in systems pharmacology modelling of statin pharmacokinetics and effects.

In the present study, we also tested the inhibitory effects of the statin acids on their pharmacological target in the liver, HMG-CoA reductase. While previous studies have determined these effects using radiometric assays or spectrophotometry to measure NADPH consumption (Kathawala, 1991; Holdgate *et al.*, 2003; Perchellet *et al.*, 2009), we used LC-MS/MS to measure mevalonolactone concentrations. Overall, our findings are in good agreement with literature data (**Supp. Table 5**). Our IC_{50} value obtained for pravastatin (13 nM), however, is 4-5 fold lower than previous measurements (McTaggart *et al.*, 2001; Perchellet *et al.*, 2009). The low value is supported by our preliminary experiment, in which the IC_{50} of pravastatin was 15 nM (data not shown). 3R,5S-fluvastatin ($IC_{50} = 9$ nM) was about 12 times more active than its 3S,5R-enantiomer ($IC_{50} \sim 100$ nM). Whereas the IC_{50} of 3R,5S-fluvastatin was between its typical unbound peak concentration in plasma and in the portal vein, that of 3S,5R-fluvastatin largely exceeded its clinically relevant unbound concentrations (**Fig. 4**). Likewise, the IC_{50} value of simvastatin acid (19.7 nM) exceeded its $C_{max,u}$ by 35-fold. On the other hand, its concentrations in the portal vein may be higher. Furthermore, simvastatin acid is a substrate of the hepatic uptake transporter OATP1B1 *in vivo* (Pasanen *et al.*, 2006), indicating that its intracellular hepatocyte concentrations are likely higher than those in the surrounding blood stream. For all other parent statins acids, the IC_{50} values obtained were close to or below their typical unbound peak concentrations in plasma and in the portal vein.

Taken together, we comprehensively investigated the *in vitro* metabolism and pharmacodynamics of statins. Together with drug transport and clinical data, our findings are applicable for use in systems pharmacology models to prospectively predict the pharmacokinetics and pharmacological effects of statins at different dosages.

Acknowledgements

The authors would like to thank Jouko Laitila for skillful technical assistance and help with the experiments.

Authorship Contributions

Participated in research design: Filppula, Hirvensalo, Parviainen, Niemi

Conducted experiments or drug concentration analysis: Filppula, Hirvensalo, Parviainen, Ivaska, Lönnberg, Deng, Viinamäki, Kurkela, Neuvonen

Performed data analysis: Filppula, Hirvensalo, Parviainen, Ivaska

Wrote or contributed to the writing of the manuscript: Filppula, Hirvensalo, Parviainen, Ivaska, Lönnberg, Deng, Viinamäki, Kurkela, Neuvonen, Niemi

References

Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, and La Du BN (2000) Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. *Drug Metab Dispos* 28:1335-1342.

Boberg M, Vrana M, Mehrotra A, Pearce RE, Gaedigk A, Bhatt DK, Leeder JS, and Prasad B (2017) Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants. *Drug Metab Dispos* 45:216-223.

Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP, and et al. (1991) Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. *Arch Intern Med* 151:43-49.

Corsini A, Maggi FM, and Catapano AL (1995) Pharmacology of competitive inhibitors of HMG-CoA reductase. *Pharmacol Res* 31:9-27.

Dujovne CA, Chremos AN, Pool JL, Schnaper H, Bradford RH, Shear CL, Higgins J, Downton M, Franklin FA, Nash DT, and et al. (1991) Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. *Am J Med* 91:25S-30S.

Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP, and Robinson WT (1999) The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. *Drug Metab Dispos* 27:410-416.

Fujino H, Saito T, Tsunenari Y, Kojima J, and Sakaeda T (2004) Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. *Xenobiotica* 34:961-971.

Fujino H, Yamada I, Shimada S, Yoneda M, and Kojima J (2003) Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. *Xenobiotica* 33:27-41.

Gertz M, Harrison A, Houston JB, and Galetin A (2010) Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. *Drug Metab Dispos* 38:1147-1158.

Gertz M, Houston JB, and Galetin A (2011) Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. *Drug Metab Dispos* 39:1633-1642.

Giacomini KM, Balimane PV, Cho SK, Eadon M, Edeki T, Hillgren KM, Huang SM, Sugiyama Y, Weitz D, Wen Y, Xia CQ, Yee SW, Zimdahl H, Niemi M, and International Transporter C (2013) International Transporter Consortium commentary on clinically important transporter polymorphisms. *Clin Pharmacol Ther* 94:23-26.

Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, and Platt R (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. *JAMA* 292:2585-2590.

Hirvensalo P, Tornio A, Neuvonen M, Kiander W, Kidron H, Paile-Hyvarinen M, Tapaninen T, Backman JT, and Niemi M (2019) Enantiospecific Pharmacogenomics of Fluvastatin. *Clin Pharmacol Ther* 106:668-680.

Hoffmann M and Nowosielski M (2008) DFT study on hydroxy acid-lactone interconversion of statins: the case of atorvastatin. *Org Biomol Chem* 6:3527-3531.

Holdgate GA, Ward WH, and McTaggart F (2003) Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. *Biochem Soc Trans* 31:528-531.

Honda A, Mizokami Y, Matsuzaki Y, Ikegami T, Doy M, and Miyazaki H (2007) Highly sensitive assay of HMG-CoA reductase activity by LC-ESI-MS/MS. *J Lipid Res* 48:1212-1220.

Houston JB and Galetin A (2008) Methods for predicting in vivo pharmacokinetics using data from in vitro assays. *Curr Drug Metab* 9:940-951.

Itkonen MK, Tornio A, Neuvonen PJ, Niemi M, and Backman JT (2015) Clopidogrel Does Not Significantly Affect the Pharmacokinetics of Simvastatin: A Crossover Study in Healthy Volunteers. *Clinical Pharmacology & Therapeutics* 97:S43-S43.

Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, and Sugiyama Y (1998) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. *Annu Rev Pharmacol Toxicol* 38:461-499.

Jamei M (2016) Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance. *Curr Pharmacol Rep* 2:161-169.

Jemal M, Ouyang Z, Chen BC, and Teitz D (1999) Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry. *Rapid Commun Mass Spectrom* 13:1003-1015.

Johnson TN and Rostami-Hodjegan A (2011) Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. *Pediatric Anesthesia* 21:291-301.

Kantola T, Kivisto KT, and Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. *Clin Pharmacol Ther* 64:58-65.

Kathawala FG (1991) HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia. *Med Res Rev* 11:121-146.

Kenny JR, Mukadam S, Zhang C, Tay S, Collins C, Galetin A, and Khojasteh SC (2012) Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction. *Pharm Res* 29:1960-1976.

Keskitalo JE, Kurkinen KJ, Neuvonen M, Backman JT, Neuvonen PJ, and Niemi M (2009a) No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. *Br J Clin Pharmacol* 68:207-213.

Keskitalo JE, Pasanen MK, Neuvonen PJ, and Niemi M (2009b) Different effects of the ABCG2 c.421C > A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. *Pharmacogenomics* 10:1617-1624.

Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, and Niemi M (2009c) ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. *Clin Pharmacol Ther* 86:197-203.

Kitazawa E, Tamura N, Iwabuchi H, Uchiyama M, Muramatsu S, Takahagi H, and Tanaka M (1993) Biotransformation of pravastatin sodium (I). Mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium. *Biochem Biophys Res Commun* 192:597-602.

Lehtisalo M, Keskitalo JE, Tornio A, Lapatto-Reiniluoto O, Deng F, Jaatinen T, Viinamaki J, Neuvonen M, Backman JT, and Niemi M (2020) Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin. *Cts-Clinical and Translational Science*.

Li Z, Zhang J, Zhang Y, and Zuo Z (2019) Role of esterase mediated hydrolysis of simvastatin in human and rat blood and its impact on pharmacokinetic profiles of simvastatin and its active metabolite in rat. *J Pharm Biomed Anal* 168:13-22.

Liederer BM and Borchardt RT (2006) Enzymes involved in the bioconversion of ester-based prodrugs. *J Pharm Sci* 95:1177-1195.

McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, and Warwick M (2001) Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. *Am J Cardiol* 87:28B-32B.

Neuvonen PJ, Niemi M, and Backman JT (2006) Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. *Clin Pharmacol Ther* 80:565-581.

Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. *Drug Metab Dispos* 27:1350-1359.

Obach RS, Walsky RL, and Venkatakrisnan K (2007) Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. *Drug Metabolism and Disposition* 35:246-255.

Pasanen MK, Neuvonen M, Neuvonen PJ, and Niemi M (2006) SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. *Pharmacogenet Genomics* 16:873-879.

Pazzucconi F, Dorigotti F, Gianfranceschi G, Campagnoli G, Sirtori M, Franceschini G, and Sirtori CR (1995) Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity. *Atherosclerosis* 117:189-198.

Perchellet JP, Perchellet EM, Crow KR, Buszek KR, Brown N, Ellappan S, Gao G, Luo D, Minatoya M, and Lushington GH (2009) Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins. *Int J Mol Med* 24:633-643.

Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, Pearson PG, and Baillie TA (2002) Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. *Drug Metab Dispos* 30:505-512.

Rostami-Hodjegan A and Tucker G (2004) 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. *Drug Discov Today Technol* 1:441-448.

Sager JE, Yu J, Ragueneau-Majlessi I, and Isoherranen N (2015) Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification. *Drug Metab Dispos* 43:1823-1837.

Thompson PD, Clarkson P, and Karas RH (2003) Statin-associated myopathy. *JAMA* 289:1681-1690.

Wang X, Zhu HJ, and Markowitz JS (2015) Carboxylesterase 1-mediated drug-drug interactions between clopidogrel and simvastatin. *Biol Pharm Bull* 38:292-297.

Varma MV, Bi YA, Kimoto E, and Lin J (2014) Quantitative prediction of transporter- and enzyme-mediated clinical drug-drug interactions of organic anion-transporting polypeptide 1B1 substrates using a mechanistic net-effect model. *J Pharmacol Exp Ther* 351:214-223.

Watanabe T, Kusuhara H, Maeda K, Shitara Y, and Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. *J Pharmacol Exp Ther* 328:652-662.

Venkatakrishnan K and Rostami-Hodjegan A (2019) Come Dance With Me: Transformative Changes in the Science and Practice of Drug-Drug Interactions. *Clin Pharmacol Ther* 105:1272-1278.

Vickers S, Duncan CA, Vyas KP, Kari PH, Arison B, Prakash SR, Ramjit HG, Pitzenberger SM, Stokker G, and Duggan DE (1990) In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. *Drug Metab Dispos* 18:476-483.

Yamada I, Fujino H, Shimada S, and Kojima J (2003) Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: similarities and difference in the metabolism of pitavastatin in monkeys and humans. *Xenobiotica* 33:789-803.

DMD-AR-2021-000406

Manuscript for *Drug Metabolism and Disposition*, April 2021

Yebyo HG, Aschmann HE, Kaufmann M, and Puhan MA (2019) Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. *Am Heart J* 210:18-28.

Footnotes

- a)** [#] This work was supported by the European Research Council (ERC) Consolidator Grant [Grant Agreement number 725249].
- b)** The authors declare no conflict of interest.
- c)** Parts of this work are included in the Master's Thesis of Heli Parviainen and Advanced Studies Thesis of Vilma E. Ivaska.
- d)** Reprint requests can be addressed to Prof. Mikko Niemi, P.O. Box 20, 00014 University of Helsinki, Finland, E-mail: mikko.niemi@helsinki.fi

Legends for Figures

Fig. 1. Intrinsic clearance values of the tested statins obtained in the depletion experiment in HLMs (A) and HIMs (B). The intrinsic clearance (CL_{int}) values obtained in incubations fortified with either NADPH (only in HLM incubations) or NADPH+UDPGA (both HLM and HIM incubations) are shown. The protein concentration was 0.2 mg/ml in all incubations, except for simvastatin HLM incubations (0.1 mg/ml). The data represent mean and standard deviation values of triplicate incubations, and they have been corrected for potential depletion in corresponding incubations lacking cofactors (negative controls). ATOR, atorvastatin; FLU, fluvastatin; HIM, human intestine microsome; HLM, human liver microsome; lac, lactone; PITA, pitavastatin; PRA, pravastatin; ROSU, rosuvastatin; SIM, simvastatin.

Fig. 2. Metabolism screening in recombinant CYP (A), HLC (B), and HIM (C) incubations. In the recombinant CYP screening, the mean statin concentrations remaining after a 60 min incubation with 11 recombinant CYP recombinant enzymes (0.2 mg/ml) and NADPH are shown. For comparison, the corresponding HLM data, with and without NADPH, is also included. The relative hepatic expression (%) of each CYP is shown in the panel to the left (calculated based on data available in Simcyp Simulator v.20, Certara UK Limited). In the HLC screening, no notable metabolism was observed following a 25 min incubation of statins with HLC (0.2 mg/ml), with or without PAPS. In the HIM figure, the parent statin concentrations remaining after 25 min incubation with PMSF-free HIMs (0.2 mg/ml) are shown (no cofactors included). In addition, 20 min data from the depletion experiment in normal HIMs both with and without NADPH and UDPGA are also shown. The data presented represent mean and standard deviation values of triplicate incubations. ATOR, atorvastatin; FLU, fluvastatin; HIM, human intestine microsome; HLC; human liver cytosol; HLM, human liver microsome; lac, lactone; OH, hydroxy; PAPS, 3'-phosphoadenosine 5'-phosphosulfate; PITA, pitavastatin; PMSF, phenylmethylsulfonyl fluoride; PRA, pravastatin; ROSU, rosuvastatin; SIM, simvastatin.

Fig. 3. Inhibition of statin metabolism by selected inhibitors in HLM and HIM incubations. The inhibitory effects of ketoconazole 1 μ M (CYP3A4/5), gemfibrozil glucuronide 60 μ M (CYP2C8), montelukast 5 μ M (CYP2C8), quinidine 10 μ M (CYP2D6), paroxetine 15 μ M (CYP2D6), and sulfaphenazole 10 μ M

DMD Fast Forward. Published on May 27, 2021 as DOI: 10.1124/dmd.121.000406

This article has not been copyedited and formatted. The final version may differ from this version.

(CYP2C9) on the depletion of statins were tested in HLMS (0.5 mg/ml protein in fluvastatin, pitavastatin lactone, and simvastatin acid incubations; 0.2 mg/ml in atorvastatin acid and lactone incubations; 0.1 mg/ml in simvastatin incubations) and HIMs (0.2 mg/ml). The values indicate the remaining metabolic activity in the presence of inhibitor and are the mean and standard deviation values of triplicate incubations. The values have been corrected for potential depletion in corresponding incubations lacking cofactors (negative controls). Pitavastatin lactone exhibited large variation due to limited solubility, which was observed repeatedly across experiments. Incubation with paroxetine was also carried out for pitavastatin lactone, but its depletion following the preincubation step was too low to be measured, ATOR, atorvastatin; FLU, fluvastatin; HLM, human liver microsome; HIM, human intestine microsome; lac, lactone; PITA, pitavastatin; PRA, pravastatin; SIM, simvastatin.

Fig. 4. Pharmacodynamic IC₅₀ values of statin acids in comparison to their plasma concentrations. To test the inhibitory effects of the acid forms of the statins on their pharmacological target, eight different concentrations of the test compound were incubated with HMG-CoA (20 μM) and HMG-CoA reductase (0.9 μg/ml) for 3 min. The results shown describe mean values of triplicate incubations (duplicate incubations for pitavastatin). The unbound peak concentration values in plasma ($C_{\max,u}$) and the portal vein ($C_{\max,u,portal}$) are from **Table 1**. As described therein, the $C_{\max,u,portal}$ concentrations were calculated assuming a complete absorption scenario.

ATOR, atorvastatin; FLU, fluvastatin; IC₅₀, inhibitor concentration producing 50% inhibition; OH, hydroxy; PITA, pitavastatin; PRA, pravastatin; ROSU, rosuvastatin; SIM, simvastatin.

Tables

Table 1

Calculated and measured *in vivo* plasma concentration data, and initial incubation concentrations (C_0) of the statins tested. Fraction unbound in plasma and peak concentration data in plasma and blood-to-plasma concentration ratios were collected from the University of Washington Drug Interaction Database (September 21, 2020) or from ADMET Predictor (version 10; Simulations Plus, Lanchester, CA). The concentration data of the fluvastatin enantiomers are from Hirvensalo *et al.* (2019) and those of the atorvastatin metabolites from Kantola *et al.* (1998) (single-dose studies).

Compound	BP	$f_{u,p}$	C_{max} (μM)	$C_{max,u}$ (μM)	C_{gut}^b (μM)	C_{ent}^c (μM)	$C_{ent,u}^c$ (μM)	$C_{max,portal}^d$ (μM)	$C_{max,portal,u}$ (μM)	C_0 in HLMS, HLC, rCYPs (μM)	C_0 in HIMS (μM)
Atorvastatin	0.667 ^a	0.02	0.31 (40 mg)	0.00062	290	8.7	0.69	2.5	0.051	0.05	1
Atorvastatin lactone	0.716 ^a	0.04 ^a	0.0070 (40 mg)	0.00028	n/a	n/a	n/a	n/a	n/a	0.05	1
2-hydroxyatorvastatin	0.673 ^a	0.05 ^a	0.017 (40 mg)	0.00085	n/a	n/a	n/a	n/a	n/a	0.05	n/d
2-hydroxyatorvastatin lactone	0.725 ^a	0.05 ^a	0.026 (40 mg)	0.0013	n/a	n/a	n/a	n/a	n/a	0.05	n/d
4-hydroxyatorvastatin	0.672 ^a	0.06 ^a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0.05	n/d
4-hydroxyatorvastatin lactone	0.721 ^a	0.05 ^a	0.0032 (40 mg)	0.00016	n/a	n/a	n/a	n/a	n/a	0.05	n/d
3R,5S-Fluvastatin	0.676 ^a	0.01	0.37 (40 mg)	0.0037	97	2.9	0.74	1.9	0.019	0.05	1
3S,5R-Fluvastatin	0.676 ^a	0.01	0.38 (40 mg)	0.0038	97	2.9	0.74	1.9	0.019	0.05	1

Compound	BP	$f_{u,p}$	C_{max} (μM)	$C_{max,u}$ (μM)	C_{gut}^b (μM)	C_{ent}^c (μM)	$C_{ent,u}^c$ (μM)	$C_{max,portal}^d$ (μM)	$C_{max,u,portal}$ (μM)	C_0 in HLMS, HLC, rCYPs (μM)	C_0 in HIMs (μM)
Pitavastatin	0.695 ^a	0.04	0.16 (4 mg)	0.0064	19	0.57	0.53	0.30	0.012	0.04	1
Pitavastatin lactone	0.753 ^a	0.05 ^a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0.03	1
Pravastatin	0.662 ^a	0.52	0.079 (40 mg)	0.041	380	11	11	3.0	1.6	0.1	1
Rosuvastatin	0.674 ^a	0.12	0.036 (40 mg)	0.0043	660	20	19	5.1	0.62	0.01	0.2
Simvastatin (lactone)	0.76 ^a	0.06	0.023 (40 mg)	0.0013	380	12	0.0023	2.6	0.16	0.05	0.05
Simvastatin acid	0.658 ^a	0.07 ^a	0.008 (40 mg lactone)	0.00056	n/a	n/a	n/a	n/a	n/a	0.05	0.05

BP, blood-to-plasma concentration ratio; C_{gut} , concentration in gut lumen; C_{ent} , enterocytic concentration; C_0 , initial incubation concentration; C_{max} , peak concentration in plasma; $C_{max,portal}$, peak concentration in portal vein; $f_{u,p}$, unbound fraction in plasma; HLC, human liver cytosol; HIMs, human intestine microsomes; HLMS, human liver microsomes; n/a, not available; n/d, not determined; u , unbound.

^a Predicted value.

^b C_{gut} calculated according to dose/250 ml.

^c C_{ent} calculated according to $\text{dose} \times k_{abs} \times f_a / Q_{ent}$, where k_{abs} is the absorption rate constant, f_a , fraction absorbed into the gut wall and Q_{ent} the enterocytic blood flow (Rostami-Hodjegan and Tucker, 2004). A complete absorption scenario was assumed, using $f_a=1$, and standard values of $k_{abs}=0.03$ 1/min and $Q_{ent}=0.248$ L/min (Obach *et al.*, 2007; Kenny *et al.*, 2012). Unbound concentrations were obtained by multiplying C_{ent} with unbound fraction in enterocytes ($f_{u,ent}$). $f_{u,ent}$ values (not shown) were predicted in Simcyp Simulator v.19 (Certara UK Limited).

^d $C_{\max, \text{portal}}$ calculated according to $C_{\max} + \text{dose} \times k_{\text{abs}} \times f_a / Q_{\text{hep}}$, where Q_{hep} is the hepatic blood flow (Ito *et al.*, 1998). A complete absorption scenario was assumed, using $f_a=1$, and standard values of $k_{\text{abs}}=0.03$ 1/min and $Q_{\text{hep}}=20.7$ ml/min/kg (Houston and Galetin, 2008). For the calculations, the C_{\max} in plasma was converted to its corresponding value in blood according to $C_{\max} \times \text{BP}$. Subsequently, the obtained $C_{\max, \text{portal}}$ in blood was converted to plasma concentration by dividing it by BP.

Table 2

The *in vitro* pharmacodynamic effects of statin acids. To test the inhibitory effects of the acid forms of the statins on their pharmacological target, eight different concentrations of the test compound were incubated with HMG-CoA (20 μ M) and HMG-CoA reductase (0.9 μ g/ml) for 3 min. The data represent mean and standard deviation values of triplicate incubations (duplicate incubations for pitavastatin).

Compound	IC ₅₀ (nM)
Atorvastatin	13.1 \pm 3.2
2-hydroxyatorvastatin	12.1 \pm 4.2
4-hydroxyatorvastatin	~100 ^a
3R,5S-fluvastatin	8.58 \pm 2.61
3S,5R-fluvastatin	~100 ^a
Pitavastatin	12.4 \pm 1.8
Pravastatin	12.6 \pm 3.7
Rosuvastatin	4.37 \pm 1.13
Simvastatin acid	19.7 \pm 2.0

IC₅₀, inhibitor concentration producing 50% inhibition.

^a The highest concentrations tested were 100 and 500 nM.

Figure 1




Figure 2




Figure 3










Figure 4



Supporting Information

Comparative hepatic and intestinal metabolism and pharmacodynamics of statins

Anne M. Filppula, Päivi Hirvensalo, Heli Parviainen, Vilma E. Ivaska, K. Ivar Lönnberg, Feng Deng, Jenni Viinamäki, Mika Kurkela, Mikko Neuvonen, Mikko Niemi

Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland (A.M.F., P.H., H.P., V.E.I., K.I.L., F.D., J.V., M.K., M.Ne., M.Ni.)

Individualized Drug Therapy Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland (A.M.F., P.H., H.P., V.E.I., K.I.L., F.D., J.V., M.K., M.Ne., M.Ni.)


Department of Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland (M.Ni.)

Corresponding author: Prof. Mikko Niemi, e-mail: mikko.niemi@helsinki.fi

Manuscript number: DMD-AR-2021-000406


Journal title: Drug Metabolism & Disposition

Comparative hepatic and intestinal metabolism and pharmacodynamics of statins



Supplementary Fig. 1.

Acid-lactone conversion in human intestine microsomal incubations. In human intestine microsomal depletion experiments, marginal lactone formation (below the quantification limit) was observed for pitavastatin in incubations fortified with NADPH + UDPGA. For atorvastatin lactone, acid concentrations increased up to 8% and 13% of the initial lactone concentration in NADPH+UDPGA and no cofactor incubations. In NADPH incubations, no increase in acid concentrations was observed. For simvastatin (lactone), there seemed to be an increase in acid concentrations in incubations lacking cofactors but not in those containing cofactors.



Supplementary Fig. 2.

The kinetics of mevalonate formation by HMG-CoA reductase was best described by a substrate inhibition model. In pharmacodynamic experiments, HMG-CoA was incubated with HMG-CoA reductase (0.9 $\mu\text{g/ml}$) and NADPH in buffer for 3 min. The results shown describe mean and standard deviation values of triplicate incubations. HMG-CoA, 3-hydroxy-3-methylglutaryl coenzyme A; K_i , inhibition constant; K_m , Michaelis-Menten constant; V_{max} , maximal reaction rate.

Supplementary Tables

Supplementary Table 1.

The characteristic multiple reaction monitoring (MRM) transitions of the analytes and internal standards.

Analyte	Analyte mass-to-charge ratios (<i>m/z</i>)	Internal standard (concentration in stop solution)	Internal standard mass-to-charge ratios (<i>m/z</i>)	Ionization (+/-)
Atorvastatin	559.1-440.1	Atorvastatin-d5 (100 nM)	564.1-445.1	+
Atorvastatin lactone	541.1-448.1	Atorvastatin lactone-d5 (100 nM)	546.1-453.1	+
2-hydroxyatorvastatin	575.1-440.1	2-hydroxyatorvastatin-d5 (40 ng/ml)	580.1-445.1	+
2-hydroxyatorvastatin lactone	557.1-448.1	2-hydroxyatorvastatin lactone-d5 (40 ng/ml)	562.1-453.1	+
4-hydroxyatorvastatin	575.1-440.1	4-hydroxyatorvastatin-d5 (30 ng/ml)	580.1-445.1	+
4-hydroxyatorvastatin lactone	557.1-448.1	4-hydroxyatorvastatin lactone-d5 (30 ng/ml)	562.1-453.1	+
3R,5S-Fluvastatin	410.1-348.1	Fluvastatin-d8 (100 nM)	418.1-356.1	-
3S,5R-Fluvastatin	410.1-348.1	Fluvastatin-d8 (100 nM)	418.1-356.1	-
Pitavastatin	422.1-290.1	Pitavastatin-d5 (100 nM)	427.1-295.1	+
Pitavastatin lactone	404.1-290.1	Pitavastatin-d5 (100 nM)	427.1-295.1	+
Pravastatin	442.1-269.1	Pravastatin-d9 (100 nM)	451.1-269.1	+
Rosuvastatin	482.1-258.1	Rosuvastatin-d6 (100 nM)	488.1-264.1	+
Simvastatin (lactone)	436.1-285.1	Simvastatin (lactone)-d6 (50 nM)	442.1-285.1	+
Simvastatin acid	437.1-303.1	Simvastatin acid-d6 (50 nM)	443.1-303.1	+

Supplementary Table 2.

Incubation concentrations (C_0) of the statin compounds tested and literature K_m values from HLM and recombinant CYP and UGT incubations, collected from the University of Washington Drug Interaction Database (September 16, 2020). K_m values from disease HLMs (e.g. diabetic HLM) and variant rCYP values were excluded.

Compound	C_0 in HLMs, HLC, rCYPs (μM)	C_0 in HIMs (μM)	Literature median K_m values in HLMs (μM)	Literature median K_m values in rCYPs and rUGTs (μM)
Atorvastatin	0.05	1	31 (range 1.2-49) (n=15)	30 (range 4-55) (n=13)
Atorvastatin lactone	0.05	1	6.3 (range 0.62-14) (n=7)	37 (range 1.4-64) (n=6)
2-hydroxyatorvastatin	0.05	n/d	n/a	n/a
2-hydroxyatorvastatin lactone	0.05	n/d	n/a	n/a
4-hydroxyatorvastatin	0.05	n/d	n/a	n/a
4-hydroxyatorvastatin lactone	0.05	n/d	n/a	n/a
3R,5S-Fluvastatin	0.05	1	Racemic: 0.5 (0.2-0.7) (n=3)	Racemic: 2.8 (1.1-7.1) (n=5)
3S,5R-Fluvastatin	0.05	1	Racemic: 0.5 (0.2-0.7) (n=3)	Racemic: 2.8 (1.1-7.1) (n=5)
Pitavastatin	0.04	1	51 (49-78) (n=3)	115 (10-220) (n=2)
Pitavastatin lactone	0.03	1	n/a	n/a
Pravastatin	0.1	1	HLMs: 8,889 (3,480-20,987) (n=4) HIMs: 4,925 (4,560-5,290) (n=2)	n/a
Rosuvastatin	0.01	0.2	n/a	220 (range 16-259) (n=3)
Simvastatin (lactone)	0.05	0.05	14 (range 2.1-36) (n=8)	35 (n=1)
Simvastatin acid	0.05	0.05	62 (range 47-416) (n=4)	28 (range 16-88) (n=6)

Comparative hepatic and intestinal metabolism and pharmacodynamics of statins

C_0 , initial incubation concentration; HIMs, human intestine microsomes; HLMS, human liver microsomes; K_m , Michaelis-Menten constant; n/a, not available; rCYP, recombinant CYP; rUGT, recombinant uridine 5'-diphospho-glucuronosyltransferase.

Supplementary Table 3.

Comparison of CL_{int} values obtained in the depletion experiment in NADPH-supplemented HLMs with those found in the literature. The CL_{int} values (mean of triplicates) of the present experiments have been corrected for potential depletion in negative controls. In addition, previous CL_{int} data from depletion studies were collected from the literature (Fujino *et al.*, 2003; Fujino *et al.*, 2004; Gertz *et al.*, 2010; Gertz *et al.*, 2011; Nishimuta *et al.*, 2013; Varma *et al.*, 2014; Hirvensalo *et al.*, 2019) and metabolite formation CL_{int} data from the University of Washington Drug Interaction Database (September 16, 2020).

Compound	f _{u,mic} at 0.2 mg/ml	HLM CL _{int} (μl/min/mg)	HLM CL _{int,u} (μl/min/mg) ^a	Literature median HLM CL _{int} (μl/min/mg) ^b (n = number of studies)
Atorvastatin	0.683 ± 0.049	37.5 ± 4.2	54.9 ± 6.2	Depletion: 16 (range 3.0-59) (n=4) Metabolite formation: 13 (range 4.1-46) (n=8)
Atorvastatin lactone	0.238 ± 0.025	3,740 ± 502	15,700 ± 2110	Depletion: 1,892 (n=1) Metabolite formation: 923 (range 4.2-2,949) (n=3)
2-hydroxyatorvastatin	0.530 ± 0.036	6.27 ± 0.64	11.8 ± 1.2	n/a
2-hydroxyatorvastatin lactone	0.216 ± 0.015	843 ± 82	3,900 ± 379	n/a
4-hydroxyatorvastatin	0.510 ± 0.040	79.9 ± 13	157 ± 25	n/a
4-hydroxyatorvastatin lactone	0.482 ± 0.093	122 ± 13	252 ± 28	n/a
3R,5S-Fluvastatin	0.747 ± 0.019	19.3 ± 2.93	25.8 ± 3.9	Depletion: 39 (n=1) Depletion (racemic): 33 (range 6-76) (n=3) Metabolite formation (racemic): 67 (range 23-68) (n=3)
3S,5R-Fluvastatin	0.735 ± 0.015	14.8 ± 1.8	20.2 ± 2.4	Depletion: 33 (n=1) Depletion (racemic): 33 (range 6-76) (n=3) Metabolite formation (racemic): 67 (range 23-68) (n=3)

Comparative hepatic and intestinal metabolism and pharmacodynamics of statins

Compound	$f_{u,mic}$ at 0.2 mg/ml	HLM CL_{int} (μ l/min/mg)	HLM $CL_{int,u}$ (μ l/min/mg) ^a	Literature median HLM CL_{int} (μ l/min/mg) ^b (n = number of studies)
Pitavastatin	0.948 \pm 0.051	<0.1	<0.1	Depletion: 1.4 (range 0.25-2.5) (n=2) Metabolite formation: 2.52 (range 1.9-3.1) (n=3)
Pitavastatin lactone	0.186 \pm 0.066	23.6 \pm 6.3	124 \pm 34	Depletion: 5 (range 4.6-5.4) (n=2)
Pravastatin	0.739 \pm 0.087	<0.1	<0.1	Depletion: 0 (n=1) Metabolite formation: 0.017 (range 0.0055-0.026) (n=4)
Rosuvastatin	0.768 \pm 0.092	<0.1	<0.1	Depletion: 0.55 (range: 0-1.1) (n=2) Glucuronide formation: 0.5 (n=1)
Simvastatin (lactone)	0.147 \pm 0.008 (at 0.1 mg/ml)	7,420 \pm 599	50,490 \pm 4070	Depletion: 4,000 (range 1,959-7,100) (n=3) Metabolite formation: 86 (range 37-287) (n=8)
Simvastatin acid	0.660 \pm 0.039	44.3 \pm 3.9	67.2 \pm 5.9	Depletion: 28 (n=1) Metabolite formation: 18 (range 0.4-20) (n=4)

CL_{int} , intrinsic clearance; $CL_{int,u}$, unbound intrinsic clearance; $f_{u,mic}$, fraction unbound in microsomes; HLM, human liver microsome.

^a Corrected for nonspecific binding in HLMs, using the measured $f_{u,mic}$ values.

^b Correction for nonspecific binding unknown.

Supplementary Table 4.

Comparison of CL_{int} values obtained in HIM incubations with those found in the literature. The CL_{int} are from Gertz *et al.* (2011); Nishimuta *et al.* (2013) and the University of Washington Drug Interaction Database (September 16, 2020). The CL_{int} values (mean of triplicates) of the present experiments have been corrected for potential depletion in negative controls.

Compound	f _{u,mic} at 0.2 mg/ml	HIM CL _{int} (μl/min/mg) ^a	HIM CL _{int,u} (μl/min/mg) ^b	Literature median HIM CL _{int} (μl/min/mg) ^c (n = number of studies)
Atorvastatin	n/d	<0.1	<0.1	Depletion: 14 (n=1)
Atorvastatin lactone	0.637 ± 0.027	724 ± 20	1,140 ± 30	n/a
Pitavastatin	0.871 ± 0.053	7.0 ± 1.0	8.0 ± 1.2	n/a
Pravastatin	n/d	<0.1	<0.1	Metabolite formation: 0.011 (range: 0.006-0.016) (n=2)
Simvastatin (lactone)	0.068 ± 0.029	1,540 ± 20	22,670 ± 320	Depletion: 1,900 (range 1,859-3,480) (n=2)

CL_{int}, intrinsic clearance; CL_{int,u}, unbound intrinsic clearance; f_{u,mic}, fraction unbound in microsomes; HIM, human intestine microsome; n/d, not determined.

^a The data of atorvastatin, pitavastatin and pravastatin are from the depletion experiment with NADPH+UDPGA, those of atorvastatin lactone and simvastatin from the inhibition experiment with NADPH.

^b Corrected for nonspecific binding in HIMs, using the measured f_{u,mic} values.

^c Correction for nonspecific binding unknown.

Supplementary Table 5

Comparison of the IC₅₀ values (nM) obtained in the present pharmacodynamic experiment with those of some previous studies.

Compound	Present study	Aoki <i>et al.</i> (1997)	Holdgate <i>et al.</i> (2003) ^a	Kathawala (1991)	McTaggart <i>et al.</i> (2001)	Perchellet <i>et al.</i> (2009)
Atorvastatin	13.1 ± 3.2	n/d	8.0	n/d	8.2	n/d
2-hydroxyatorvastatin (<i>ortho</i> -hydroxyatorvastatin)	12.1 ± 4.2	n/d	n/d	n/d	n/d	n/d
4-hydroxyatorvastatin (<i>para</i> -hydroxyatorvastatin)	~100 ^b	n/d	n/d	n/d	n/d	n/d
3R,5S-fluvastatin	8.58 ± 2.61	n/d	28 ^c	2.4	27.6 ^c	172.8 ^c
3S,5R-fluvastatin	~100 ^b	n/d	28 ^c	80	27.6 ^c	172.8 ^c
Pitavastatin	12.4 ± 1.8	6.8	n/d	n/d	n/d	n/d
Pravastatin	12.6 ± 3.7	48	44	n/d	44.1	66.1
Rosuvastatin	4.37 ± 1.13	n/d	3.5	n/d	5.4	n/d
Simvastatin acid	19.7 ± 2.0	16	11	n/d	11.2	134
Enzyme source	Recombinant enzyme	Rat liver microsomal enzyme	Recombinant enzyme	Rat liver microsomal enzyme	Recombinant enzyme	Recombinant enzyme

IC₅₀, inhibitor concentration producing 50% inhibition; n/d, no data.

^a Inhibition constant (K_i) values.

^b The highest concentrations tested were 100 and 500 nM.

^c The fluvastatin compound tested was likely the racemic mix (not clearly stated in the paper).

References

- Aoki T, Nishimura H, Nakagawa S, Kojima J, Suzuki H, Tamaki T, Wada Y, Yokoo N, Sato F, Kimata H, Kitahara M, Toyoda K, Sakashita M, and Saito Y (1997) Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. *Arzneimittelforschung* 47:904-909.
- Fujino H, Saito T, Tsunenari Y, Kojima J, and Sakaeda T (2004) Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. *Xenobiotica* 34:961-971.
- Fujino H, Yamada I, Shimada S, Yoneda M, and Kojima J (2003) Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. *Xenobiotica* 33:27-41.
- Gertz M, Harrison A, Houston JB, and Galetin A (2010) Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. *Drug Metab Dispos* 38:1147-1158.
- Gertz M, Houston JB, and Galetin A (2011) Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. *Drug Metab Dispos* 39:1633-1642.
- Hirvensalo P, Tornio A, Neuvonen M, Kiander W, Kidron H, Paile-Hyvarinen M, Tapaninen T, Backman JT, and Niemi M (2019) Enantiospecific Pharmacogenomics of Fluvastatin. *Clin Pharmacol Ther* 106:668-680.
- Holdgate GA, Ward WH, and McTaggart F (2003) Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. *Biochem Soc Trans* 31:528-531.
- Kathawala FG (1991) HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia. *Med Res Rev* 11:121-146.
- McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, and Warwick M (2001) Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. *Am J Cardiol* 87:28B-32B.
- Nishimuta H, Nakagawa T, Nomura N, and Yabuki M (2013) Species differences in hepatic and intestinal metabolic activities for 43 human cytochrome P450 substrates between humans and rats or dogs. *Xenobiotica* 43:948-955.
- Perchellet JP, Perchellet EM, Crow KR, Buszek KR, Brown N, Ellappan S, Gao G, Luo D, Minatoya M, and Lushington GH (2009) Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins. *Int J Mol Med* 24:633-643.
- Varma MV, Bi YA, Kimoto E, and Lin J (2014) Quantitative prediction of transporter- and enzyme-mediated clinical drug-drug interactions of organic anion-transporting polypeptide 1B1 substrates using a mechanistic net-effect model. *J Pharmacol Exp Ther* 351:214-223.